Clinical trials
Recurrence trials with no applicable phase and unknown status
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
108 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 1 |
| 2005 | 1 |
| 2007 | 3 |
| 2008 | 4 |
| 2010 | 3 |
| 2011 | 1 |
| 2012 | 4 |
| 2013 | 6 |
| 2014 | 3 |
| 2015 | 6 |
| 2016 | 10 |
| 2017 | 10 |
| 2018 | 3 |
| 2019 | 9 |
| 2020 | 9 |
| 2021 | 11 |
| 2022 | 11 |
| 2023 | 10 |
| 2024 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Unknown status | 108 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Postgraduate Institute of Dental Sciences Rohtak | 4 |
| Mansoura University | 3 |
| Southwest Hospital, China | 3 |
| Centre Leon Berard | 2 |
| Children's Cancer and Leukaemia Group | 2 |
| Eastern Hepatobiliary Surgery Hospital | 2 |
| Mehmet Eşref Ulutaş | 2 |
| National Taiwan University Hospital | 2 |
| Peking Union Medical College Hospital | 2 |
| Peking University First Hospital | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Recurrence | 108 |
| Carcinoma, Hepatocellular | 11 |
| Urinary Bladder Neoplasms | 5 |
| Atrial Fibrillation | 4 |
| Disease Progression | 4 |
| Endometrial Neoplasms | 4 |
| Lymphoma | 4 |
| Neoplasm Metastasis | 4 |
| Pain | 4 |
| Leukemia | 3 |
Trials
Showing 1 to 25 of 108. Each trial links to its page on Pharma Observatory.
8 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.